Ryan Black

Advanced techniques allowed researchers to isolate T-cells involved in RA.

NFL-related organizations are looking to stymie the drop in youth participation.

Between 2012 and 2015, pod-related eye burns among toddlers increased 3000%.

The multiple sclerosis drug may become cheaper with Teva’s loss of exclusivity.

Canadian authorities today approved Sanofi/Regeneron collaboration sarilumab.

The electrode-covered vest can map the heart after capturing a single heartbeat.

NICO’s Myriad automated devices cleared for a wider range of applications.

Every year, six million children aged 4-17 see a physician regarding ADHD.

Two new treatments have been fast-tracked in Europe as sales wane domestically.

A new Australian study confirms previous findings from North America.

After a decade in limbo, Shire’s other amphetamine salt combo is back under review.

A new study leads back to the age-old question of incidence vs. diagnostics.

After spotty trials, Alcobra's MDX met its end as a potential ADHD treatment.

It's well known that arthritis doesn't mix well with other conditions. But where does healthcare go with that information?

It did not take long for the other shoe to fall.

The report documents two dozen high school deaths over 10 years between 2005 and 2014.

A study out of the University of Montreal explores newer, more accurate methods of targeting "HIV reservoirs" and tests two drugs, originally developed for cancer treatment, for their ability to bring the virus out of hiding.

The authors of a recently published study claim a novel, existing class of drugs, known as salicylanilides, are effective against C. difficile infection.

The study identified several characteristics to observe in HIV patients who develop broadly neutralizing HIV antibodies (bnAbs), which occur naturally in about one percent of those infected with the disease and could be key in an eventual vaccine. Black patients were found more likely to develop them than white.

Balaji Srinivasan and Jim O'Neill have both previously derided the FDA's role.

The only consensus seems to be that walking is good for arthritis.

A biosimilar to the world's biggest-selling drug performed well alongside it, according to top-line results announced recently.

The FDA’s decision follows the EU’s decision last month to similarly expand the scope of the drug’s approval to include more specific causes of vision loss and blindness.

Deeming Xaracoll to be a drug/device combination, the Food and Drug Administration notified Innocoll yesterday that it would not be going forward with the New Drug Application they had filed for the product in October.

From observations about butter and questions about acne to findings about flu shots and platypus venom, dozens of fascinating studies came out in 2016 regarding the disease.

Electric shocks, hot tea, and cryogenic freeze are just a few of the topics that came up in 2016 during the constant search to better understand and treat rheumatoid arthritis.

ASP0892 is an investigational DNA vaccine for the common, potentially fatal allergy.

Smoking teens, rogue genes, and mashed-up hookworms are among the many diverse, fascinating, and important asthma topics that came out of 2016.

Johns Hopkins researchers have linked a specific bacteria involved in gum disease to the processes at hand in rheumatoid arthritis. It may be premature, however, to consider flossing an aspect of joint health.

The billion-dollar combination of pegpleranib and ranibizumab failed to meet primary endpoints in studies for the treatment of age-related macular degeneration.